- FDA Drug Shortages [Internet]. 2018 [Cited 2018 Aug 15]; Available from: https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Morphine%20Sulfate%20(Astramorph%20PF,%20Duramorph,%20Infumorph)%20Injection%20(Preservative%20Free)&st=c&camefrom=tabs-1
- Piramal Critical Care, Inc. Mitigo (morphine sulphate injection)® [USPI]. 2017 [Cited 2018 Aug 15].
- Wilkes DM, Orillosa SJ, Hustak EC, et al. Efficacy, Safety, and Feasibility of the Morphine Microdose Method in Community-Based Clinics [Internet]. 2017 [cited 2018 Aug 15]; Available from: https://www.ncbi.nlm.nih.gov/pubmed/29016893
- Jason E. Pope MD, Timothy R. Deer MD, Brian M. Bruel MD, Steven Falowski MD. Clinical Uses of Intrathecal Therapy and Its Placement in the Pain Care Algorithm [Internet]. 2016 [Cited 2018 Aug 15]; Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/papr.12438
- Bloodborne Pathogens and Needlestick Prevention [Internet]. 2012 [Cited 2018 Aug 15]; Available from: https://www.osha.gov/SLTC/bloodbornepathogens/evaluation.html
- Intrathecal Morphine Microdose Method Sensory Changes [Internet]. 2018 [Cited 2018 Aug 15]; Available from: https://clinicaltrials.gov/ct2/show/NCT03395275
- Morphine Microdose Therapy Safe, Effective in Chronic Non-Cancer Pain [Internet]. 2017 [Cited 2018 Aug 21]; Available from: https://www.clinicalpainadvisor.com/chronic-pain/treating-chronic-pain-with-morphine-microdose-therapy/article/673977/
- Centers for Medicare and Medicaid Services. Physician Fee Schedule [Internet]. 2018 [Cited 2018 Aug 22]; Available from: https://www.cms.gov/apps/physicianfeeschedule/search/searchresults.aspx?Y=0&T=0&HT=0&CT=3&H1=J2274&M=5
- L. Painchart, P. Odou, JF Bussieres. Particulate Contamination Associated with the Manipulation of Drugs in Glass Ampules: A Literature Review [Internet]. 2018 [Cited 2018 Aug 15]; Available from: https://www.ncbi.nlm.nih.gov/pubmed/28800916
- Medtronic, Inc. Intrathecal Drug Delivery for Chronic Pain Literature Review [Internet]. 2016 [Cited 2018 Aug 22]; Available from: https://www.medtronic.com/content/dam/medtronic-com/professional/documents/uc200805143d-tdd-chronic-pain-lit-review.pdf
INDICATIONS AND USAGE
MITIGO (Morphine Sulfate Injection, USP – Preservative-free) is an opioid agonist, for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Important Risk Information
- Single-dose neuraxial administration may result in acute or delayed respiratory depression up to 24 hours. Because of the risk of severe adverse reactions when MITIGO is administered by the epidural or intrathecal route of administration, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose.
- Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially upon initiation or following a dose increase. Patients must be observed in a fully equipped and staffed environment for at least 24 hours after each test dose and, as indicated, for the first several days after surgery.
- MITIGO exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient’s risk before prescribing and monitor regularly for these behaviors and conditions.
- Prolonged use of MITIGO during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
- Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting in absence of resuscitative equipment
- Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity or intolerance to morphine
Neuraxial administration of MITIGO is contraindicated in patients with:
- Infection at the injection microinfusion site
- Concomitant anticoagulant therapy
- Uncontrolled bleeding diathesis
- The presence of any other concomitant therapy or medical condition which would render epidural or intrathecal administration of medication especially hazardous.
WARNINGS AND PRECAUTIONS
- Risk of Inflammatory Masses: Monitor patients receiving continuous infusion of MITIGO via indwelling intrathecal catheterfor new signs or symptoms of neurologic impairment.
- Risk of Tolerance and Myoclonic Activity: Monitor patients for unusual acceleration of neuraxial morphine, which may cause myoclonic-like spasm of lower extremities. Detoxification may be required.
- Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly during initiation and titration.
- Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
- Severe Hypotension: Monitor during dosage initiation and titration. Avoid use of MITIGO in patients with circulatory shock.
- Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: Monitor for sedation and respiratory depression. Avoid use of MITIGO in patients with impaired consciousness or coma.
Most serious adverse reactions were respiratory depression, apnea, circulatory depression, respiratory arrest, shock, and cardiac arrest. Other common frequently observed adverse reactions include: sedation, lightheadedness, dizziness, nausea, vomiting, and constipation.
USE IN SPECIFIC POPULATIONS
- Pregnancy: May cause fetal harm.
- Hepatic and Renal Impairment: May affect the metabolism and excretion of MITIGO.
To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care, Inc. at 1-888-822-8431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For additional Important Risk Information, including boxed warning, see enclosed Full Prescribing Information.